Phathom Pharmaceuticals (PHAT)
(Delayed Data from NSDQ)
$10.39 USD
+0.72 (7.45%)
Updated May 14, 2024 04:00 PM ET
After-Market: $10.37 -0.02 (-0.19%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Cash flow Statements
Fiscal Year End for Phathom Pharmaceuticals, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -201.59 | -197.72 | -143.88 | -129.07 | -255.13 |
Depreciation/Amortization & Depletion | 2.45 | 2.73 | 4.12 | 1.60 | 0.42 |
Net Change from Assets/Liabilities | -13.64 | 5.44 | -27.48 | 51.72 | -9.52 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 75.20 | 43.03 | 18.63 | 6.07 | 227.73 |
Net Cash From Operating Activities | -137.58 | -146.53 | -148.62 | -69.69 | -36.51 |
Property & Equipment | -1.63 | -1.04 | -0.33 | -1.04 | -0.13 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | -25.12 |
Net Cash from Investing Activities | -1.63 | -1.04 | -0.33 | -1.04 | -25.25 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 155.59 | 24.60 | 1.94 | 89.46 | 191.47 |
Issuance (Repayment) of Debt | 39.32 | 0.00 | 42.76 | 25.00 | 113.17 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 172.68 | 95.45 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 367.58 | 120.04 | 44.71 | 114.46 | 304.65 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 228.37 | -27.53 | -104.24 | 43.73 | 242.89 |
Cash at Beginning of Period | 155.89 | 183.42 | 287.50 | 243.77 | 0.88 |
Cash at End of Period | 384.26 | 155.89 | 183.26 | 287.50 | 243.77 |
Diluted Net EPS | -3.93 | -5.05 | -3.89 | -3.88 | -22.45 |
Fiscal Year End for Phathom Pharmaceuticals, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -82.85 | -201.59 | -122.02 | -78.78 | -37.81 |
Depreciation/Amortization & Depletion | 0.69 | 2.45 | 1.70 | 1.04 | 0.64 |
Net Change from Assets/Liabilities | -7.02 | -13.64 | -14.32 | -11.91 | -16.34 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 20.17 | 75.20 | 40.86 | 27.78 | 13.84 |
Net Cash From Operating Activities | -69.02 | -137.58 | -93.78 | -61.87 | -39.67 |
Property & Equipment | -0.04 | -1.63 | -1.16 | -0.22 | -0.21 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -0.04 | -1.63 | -1.16 | -0.22 | -0.21 |
Uses of Funds
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 0.00 | 155.59 | 155.59 | 155.57 | 14.07 |
Issuance (Repayment) of Debt | 9.90 | 39.32 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 172.68 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 9.90 | 367.58 | 155.59 | 155.57 | 14.07 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -59.16 | 228.37 | 60.65 | 93.49 | -25.81 |
Cash at Beginning of Period | 384.26 | 155.89 | 155.89 | 155.89 | 155.89 |
Cash at End of Period | 325.10 | 384.26 | 216.54 | 249.38 | 130.08 |
Diluted Net EPS | -1.42 | -1.44 | -0.76 | -0.84 | -0.89 |